Although it is good to see competing mouthwashes don't work that well for OM, I think everybody on this board and in the medical community already recognized this fact.

We have the data to show Brilacidin is statistically significant to not only mitigate the symptoms of OM, but prevent it altogether. There is no doubt that we have the goods, so who is this PR trying to sway in showing Brilacidin is the drug to pursue for a solution to the OM problem? Not at all impressed w the statement " progresses through first stage of review by European Medicines Agency (EMA) regarding Scientific Advice for planned Phase 3 Program".

I would think we are far beyond the point where we are still trying to convince BP that they should partner with us. If this is for some competitive bidding support, fine, but IMO we should be beyond what this PR might lead one to believe is the current state of negotiations.